Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 3/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.48 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.48 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.43 |
| ▸ | THRA | P10827 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | CFD | P00746 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11571880 | 0.85 | SUCNR1 (0.53) | PTGER1PTGER4PTGER3PTGER2AKR1B1 | |
| SCHEMBL31062441 | 0.81 | SUCNR1 (0.44) | PTGER1PTGER4PTGER3PTGER2AKR1B1 | |
| SCHEMBL23078658 | 0.81 | HSD17B1 (0.44) | AKR1C3AKR1C2CAMK2A | |
| SCHEMBL18076565 | 0.76 | HSD17B1 (0.52) | PTGER1PTGER4PTGER3PTGER2ENPP2 | |
| SCHEMBL9105295 | 0.75 | PTGER1 (0.57) | PTGER1PTGER4PTGER3PTGER2ENPP2 | |
| SCHEMBL15564003 | 0.75 | AKR1C3 (0.56) | AKR1C3AKR1C2AKR1B1THRATHRB | |
| Resorcinol SCHEMBL8656538 | 0.75 | AKR1B1 (0.63) | AKR1B1PTGS2PTGS1CAMK2A | |
| SCHEMBL17802764 | 0.74 | CFD (0.67) | PTGER1PTGER4PTGER3PTGER2CFD | |
| SCHEMBL26680676 | 0.74 | PTGER4 (0.77) | PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL3232628 | 0.73 | AKR1B1 (0.67) | AKR1B1THRBPTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105959-A1 | Cynnamyl alcohol derivative compounds and drugs containing the compounds as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1604971-A1 | CINNAMYL ALCOHOL DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105959-A1 | Cynnamyl alcohol derivative compounds and drugs containing the compounds as active ingredient | LPL, GPR119, EBP | PTGER1 1120/4885PTGER4 1850/4885PTGER3 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.